Grace Therapeutics is a late-stage biopharma company with drug candidates addressing rare and orphan diseases, with novel drug delivery technologies that have the potential to improve the performance of marketed drugs by achieving faster onset of action and reduced side effects. GTx-104 has received FDA Orphan Drug Designation, which will provide seven years of marketing exclusivity upon NDA approval.
Cyborg Score Rationale
The FDA accepted the NDA for GTx-104 for review with a PDUFA target date of April 23, 2026, and positive Phase 3 STRIVE-ON safety trial data were presented at the 2025 Neurocritical Care meeting. The company has a market cap of ~$60M with negative earnings, though orphan drug designation and patent protection through 2043 provide competitive moats.
Top Insights
FDA acceptance of NDA for GTx-104 with April 23, 2026 PDUFA target date positions potential approval within Q2 2026
Novel method-of-use patent extends IP protection until 2043, complementing existing composition patents until 2037
Company secured $4.0 million through warrant exercises following FDA acceptance of NDA, demonstrating investor confidence
Pipeline includes GTx-102 for Ataxia-Telangiectasia and GTx-101 for postherpetic neuralgia, diversifying risk beyond lead asset
Named Competitors
Vascular neurology treatments — Traditional and novel formulations for subarachnoid hemorrhage and related conditions
Recent Developments
(November 2025) FDA accepted NDA for GTx-104 with April 23, 2026 PDUFA target date
(November 2025) Raised approximately $4.0 million through warrant exercises
(September 2025) Granted sixth U.S. patent covering IV dosing regimen extending protection to 2043
(September 2025) Presented positive Phase 3 STRIVE-ON safety trial data at Neurocritical Care meeting
Open the full interactive Grace Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.